This startup develops rapid antimicrobial susceptibility tests (ASTs) that identify effective antibiotics for serious infections within hours, significantly faster than traditional methods. Their technology helps clinicians optimize antibiotic treatment, improving patient outcomes and combating antimicrobial resistance.
Funding
Funding not disclosed
Founders
Product
Problem
Current antimicrobial susceptibility tests (ASTs) can take days to produce results, delaying the identification of effective antibiotics for patients with serious infections. This delay can lead to inappropriate antibiotic use, contributing to antimicrobial resistance and potentially worsening patient outcomes.
Solution
Cytophenix is developing FloCAST™, a rapid antimicrobial susceptibility testing platform that delivers quantitative, comprehensive, phenotypic susceptibility results in 3-5 hours. The platform uses patented technology to measure individual bacterial or fungal cells, then combines measurements from thousands to millions of cells in minutes to capture complex resistance mechanisms. Proprietary artificial intelligence analyzes the data and provides automated predictions of susceptibility, including MIC and SIR values, in customizable reports.
Target Audience
The primary target audience includes clinicians and laboratories needing faster and more accurate antimicrobial susceptibility testing for patients with serious infections.
Features
- Measures individual bacterial or fungal cells for precise susceptibility testing
- Combines measurements from thousands to millions of cells to capture complex resistance mechanisms
- Proprietary AI algorithms for automated prediction of susceptibility (MIC, SIR)
- Customizable reporting tailored to user needs
- Flow cytometry-based diagnostic test